Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Curie-Cancer and GenoSplice Technology Sign Bioinformatics Partnership Agreement

Published: Wednesday, January 30, 2013
Last Updated: Wednesday, January 30, 2013
Bookmark and Share
The innovative partnership is planned to run for several years to develop unique, high value added genomic approaches.

Curie-Cancer and GenoSplice Technology have announced that they have formed a partnership to combine their expertise.

This collaboration will provide GenoSplice with access to several Curie-Cancer technology platforms to allow it to continue to improve its services to its clients.

GenoSplice will, in turn, be included in Institut Curie research programs and will benefit from access to the intellectual property generated during the projects.

This agreement will allow GenoSplice to specifically contribute to the development of new products against cancer. The agreement also facilitates better understanding of complex diseases such as cancer through genome mapping.

Curie-Cancer, in developing Institut Curie’s industry partnership activities, chose to collaborate with GenoSplice, a specialized bioinformatics solutions provider with very high value-added genomic data analysis.

GenoSplice will use Curie-Cancer’s genomic platform to continue to offer data processing to their primary client base - large pharmaceutical laboratories, biotechnology companies and academic research centers.

The clients use GenoSplice to process the data gathered from high-speed sequencing and/or DNA microarrays, as well as to obtain a better understanding of the biological mechanisms involved with alternative splicing for their R&D projects.

One specific project in the collaboration will consist of defining a genomic map for prostate cancer. The map will be based on the analysis of data obtained from several hundred patients suffering from this type of cancer.

The goal is twofold: to better understand the mechanisms involved in this disease and to group patients in order to guide clinicians in selecting therapeutic options.

A second project regards a new therapeutic approach in cancer treatment that will use a new type of “cell penetrating peptide” molecule.

The effectiveness of one of these molecules has already been demonstrated in mice on xenograft models representative of human tumors.

The purpose of the project will be to identify the predictive markers of response to this molecule in order to select the patients who are most likely to respond positively to this new treatment.

GenoSplice contributes with expertise enabling the identification of these markers, which will then allow treatments to be administered to patients most effectively.

“Combining the skills and expertise of GenoSplice and Curie-Cancer will allow us to provide cutting-edge bioinformatics solutions that are very competitive in the field of genomics,” said Marc Rajaud, president and co-founder, GenoSplice.

“Participating in research projects with the Institut Curie, which are sometimes multi-party and involve other international research institutes, will put us at the forefront of developments in our areas of interest and will enable us to provide the best possible service to our clients,” said Pierre de la Grange, scientific director and co-founder, GenoSplice.

“In addition to the prospect of being able to provide an additional therapeutic solution for our patients, we are pleased to be able to contribute to the development of a French SME, while progressing towards a greater understanding of cancers,” says Damien Salauze, director of Curie-Cancer.

Salauze continued, “Once again it’s clear that the expertise and experimental models developed at the Institut Curie for the purposes of fundamental research also meet the needs expressed by our partners in the industry. The Carnot label we obtained in 2011 is a testament to this.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Curie-Cancer and DNA Therapeutics Partner in the Fight Against Cancers
Their clinical and translational research program has developed Dbait molecules now in Phase I clinical trial in patients with advanced melanoma.
Thursday, March 06, 2014
Curie-Cancer and Servier Continue a Renewed Partnership in Cancer Research
Their joint aim is to identify new therapeutic targets in ‘triple negative’ breast cancers.
Wednesday, January 29, 2014
Curie-Cancer and Sanofi Cooperate in Research on Ovarian Cancer
Preclinical program of translational research tasked with identifying new target proteins.
Wednesday, June 19, 2013
Curie-Cancer and Biolog-id Sign Partnership Agreement
Within the partnership, Curie-Cancer and Biolog-id will develop a pilot system of RFID tags suitable for use in tracking cancer chemotherapy preparations.
Wednesday, June 05, 2013
Curie-Cancer and Roche Strengthen Partnership
Curie-Cancer and Roche build on four years partnership by increasing translational research programs, speeding up development of new cancer treatments.
Friday, May 17, 2013
Curie-Cancer and Vygon Sign a Partnership Agreement Extension
The Curie-Cancer and Vygon partnership will extend over several years and will achieve the development of catheters and implantable ports with increased resistance to nosocomial infections, for launch on the international market.
Tuesday, April 16, 2013
Curie-Cancer Funds its First Selection of Five Late-Stage Projects
Funding of these first five projects enables Institut Curie’s discoveries to progress more rapidly to the industrial stage, making innovation available to patients more quickly.
Friday, December 14, 2012
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
Investigating the Vape
Expert independent review concludes that e-cigarettes have potential to help smokers quit.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Researchers Discover Synthesis of a New Nanomaterial
Interdisciplinary team creates biocomposite for first time using physiological conditions.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!